Bioinformatics analysis reveals a stem cell-expressed circ-Serpine2-mediated miRNA-mRNA regulatory subnetwork in the malignant progression of glioma

Guowei Li and Qing Lan*

Abstract
Background: High-grade glioma has a poor prognosis, and GSCs can have pivotal roles in glioma pathology. This study investigated GSC exosome-containing circRNA mechanisms affecting the malignant progression of glioma.

Methods: In this study, we identified differentially expressed circRNAs and constructed a circRNA-miRNA-mRNA regulatory network through circRNA sequencing/bioinformatics analysis. Then, we identified circRNAs that were upregulated in GSC23 cells and employed them as downstream targets in subsequent investigations. Such investigations included downstream target knockout to assess any influence on A172 cell proliferation, invasion, migration and apoptosis. In addition, in vivo investigations using tumor-bearing animals evaluated the in vivo influences of the selected targets.

Results: This study identified circ-Serpine2/miR-124-3p/KIF20A as a regulatory pathway in glioma. Our in vitro analysis confirmed that circ-Serpine2 could upregulate KIF20A by sponging miR-124-3p, consequently promoting A172 cell proliferation, migration and invasion. Such a signaling channel could also inhibit glioma cell apoptosis. Additionally, our research indicated that circ-Serpine2 inhibited glioma apoptosis and promoted in vivo tumor progression.

Conclusion: Circ-Serpine2 exacerbated the malignant progression of glioma mediated by the miR-124-3p/KIF20A nexus, thus providing novel predictive/prognostic biomarkers and drug targets against glioma.

Keywords: Glioma stem cell, circRNAs, Bioinformatic analysis, Malignant progression, Nexus

Introduction
High-grade glioma (WHO III-IV) is a malignant tumor that possesses reduced prognostic profiles, although glioma therapy advancements have been established. Approximately 5 in 100,000 people are newly diagnosed with glioma annually, and glioblastomas represent approximately 15% of all primary brain tumors [1–9]. Currently, surgical resection followed by concomitant radiochemotherapy is considered to be an efficient treatment. However, most of these therapies have not led to increased survival rates, and such grim realities force us to seek new treatments.

Local recurrences contribute to the poor outcomes of glioma. Increasing evidence suggests that these pathological processes are caused by tumor-initiating glioma stem cells (GSCs), and it has been documented that exosomes released by GSCs might play important roles in glioma progression [10–15]. Therefore, it is necessary to investigate the stem cell-related mechanisms that underlie...
glioma development and identify potential therapeutic targets.

In recent decades, rising quantities of cancer-related circRNAs have been observed, and several of them were found to take up oncogenic or tumor-suppressive activities within human malignancies. Multiple investigations have suggested that circRNAs induce cytoplasmic down-regulation of targeted microRNAs (miRNAs), consequently liberating downstream target transcripts of such downregulated miRNAs [16–18]. This study merged a previously developed circRNA database with the Gene Expression Omnibus (GEO) database to explore circRNA-miRNA-mRNA networks in glioma. Additionally, founded upon upregulated expression circRNA profiles in GSCs, this study developed a network of regulating molecular members that consisted of eight circRNAs, six miRNAs, and ten mRNAs using the GEO database and additional similar repositories for predictive purposes. Gene ontology (GO) annotation, Encyclopedia of Genes and Genomes (KEGG) pathway analyses and a protein–protein interaction (PPI) network were used to unravel putative regulatory mechanisms of circRNAs in the progression of glioma. Finally, we filtered out the signaling pathway (circ-Serpine2/miRNA-124–3p/KIF20A) and clarified the regulatory mechanism through expression validation and functional verification, rendering such molecular players highly appealing as novel drug targets.

**Materials and methods**

**Cell culture**

The GSC23 line was a gift from the Soochow University Stem Cell Research Group, and these cells were cultured in serum-free medium (Gibco, USA). Then, we added serum to the medium to induce GSC23 differentiation into glioma cells. A172, U251 and SVG cells were procured from Shanghai Institutes for Biological Sciences and grown in RPMI 1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA), 100 ng/mL streptomycin, and 100 U/mL penicillin (Gibco, USA). All cultures incubated at 37 °C and 5% CO2.

**Exosome isolation and identification**

Exosomes were extracted from cell culture supernatants by ultrahigh-speed centrifugation. Briefly, cell culture supernatants were differentially centrifuged (300g for 10 min, 1000g for 20 min, or 10,000g for 30 min). After filtration, the supernatant was ultracentrifuged at 100,000g for 180 min. Then, the precipitates were subjected to two phosphate-buffered saline (PBS)-washing steps, resuspended in PBS and stored at −80 °C. Exosomes were visualized by scanning electron microscopy and confirmed by protein concentration determination, and the expression levels of CD9, CD63, Annexin, and Calnexin were assessed using Western blotting.

**Scanning electron microscopic observation and measurement**

Exosomal morphologies were visually assessed by scanning electron microscopy. The GSC23 and glioma cell supernatants were collected and extracted by ultrahigh-speed centrifugation, and a small amount of white sediment was observed at the bottom of the tube after centrifugation. Then, it was dissolved in 1 × PBS, fixed with 2.5% glutaraldehyde and dehydrated. Finally, we used a scanning electron microscope for observation. The samples were diluted with PBS, and 100 μL dilution was added to the sample plate. An Izon particle analyzer and a high-resolution tunable resistance pulse were used to detect the particle diameter.

**CircRNA sequencing**

Total RNA was extracted from GSC23/GSC23-differentiated cells with TRIzol (Life Technologies,™, Carlsbad, CA, USA). Before constructing RNA-seq libraries, both the Ribo-Zero rRNA Removal Kit (Illumina, San Diego, CA, USA) and CircRNA Enrichment Kit (Cloud-seq, USA) were employed to attain rRNA removal and cir-cRNA enrichment. The RNA-seq libraries were developed through pretreatment of RNAs with the TruSeq® Stranded Total RNA Library Prep Kit (Illumina™, San Diego, CA, USA). All libraries were denatured into single-stranded DNA molecules, placed onto flow cells, amplified in situ as clusters and consequently sequenced (150 cycles) on an Illumina HiSeq® 4000 Sequencer (Illumina™, San Diego, CA, USA).

**Microarray data and RNA sequencing data**

Microarray datasets were retrieved from the GEO database. CircRNA sequencing was conducted in the Experimental Center of the Second Affiliated Hospital of Soochow University.

**Expression profile assessments**

CircRNA expression profiling for GSC23- and GSC23-differentiated cells (3 replicates each) was obtained by circRNA microarray technology. Cell circRNA expression difference analysis was performed using the limma package in R, and |logFC|> 1 and P < 0.05 were considered statistically significant.

According to gene ceRNA theory, highly expressed circRNAs may release miRNAs from their target mRNAs, thus promoting mRNA expression. Therefore, specifically overexpressed circRNAs in GSCs may act on miRNAs in glioma and result in negative regulation, thereby indirectly promoting abnormally high mRNA expression in...
glioma cells. To assess the interactions between circRNAs in GSCs and miRNAs in glioma cells, we first used the GEOquery package in R to determine the miRNA expression profile in the GSE25632 dataset in the GEO database (5 normal controls and 82 glioma tissues). The miRNA expression profile was annotated through the GPL8179 platform, and differential analysis was performed with the limma package in R. |logFC|> 1 and P < 0.05 were considered statistically significant.

To further explore the mRNA regulated by miRNA in glioma cells and specifically highly expressed circRNAs in GSCs, we used the GEOquery package in R to determine the mRNA expression profile from the GSE103227 dataset in the GEO database (including 5 normal controls and 5 glioma tissues). Differential analysis was performed with the limma package in R, with |logFC|> 1 and P < 0.05 being considered statistically significant.

CircRNA-miRNA-mRNA regulatory network development
We used the miRNA-circRNA module on the StarBase v3.0 website (http://starbase.sysu.edu.cn) to predict the targeted relationship between the miRNAs and the specifically highly expressed circRNAs in GSCs. Then, a Venn diagram was used to determine the intersection between miRNAs specifically targeting highly expressed circRNAs in GSCs and miRNAs that are specifically expressed at low levels in glioma cells. Thus, we identified target miRNAs and used Cytoscape 3.8.2 to draw the circRNA-miRNA regulatory network of specifically highly expressed circRNAs in GSCs that may participate in glioma gene regulation.

We used the miRTarBase website (http://miRTarBase.mbc.nctu.edu.tw/php/index.php) for target correlation prediction between miRNAs and miRNAs in a regulatory network of circRNAs that are highly expressed in GSCs and glioma miRNAs. Then, a Venn diagram was used to determine the intersection between miRNAs specifically targeting highly expressed circRNAs in GSCs and miRNAs that are specifically expressed at low levels in glioma cells; thus, we identified target miRNAs and used Cytoscape 3.8.2 to draw the circRNA-miRNA regulatory network of specifically highly expressed circRNAs in GSCs that may participate in glioma gene regulation.

The circRNA-miRNA-mRNA regulatory network was developed by combining circRNA-miRNA/miRNA-mRNA pairs. Ultimately, network visualization was obtained through Cytoscape 3.8.2.

Functional enrichment analysis
The R-based ‘Cluster Profiler package’ was employed for GO/KEGG pathway enrichment analysis of mRNA in the miRNA-mRNA regulatory network, followed by visualization of the results through Cytoscape 3.8.2. In addition, all such GO/KEGG outcomes would be < 0.05, and the P and Q values of KEGG analysis would be < 0.05.

Construction of the PPI network, module and immune-correlation analysis
We used CGGA data and Kaplan–Meier survival analysis to delve into deeper assessment of the interactions of mRNA expression levels and the prognosis of glioma patients. Consequently, glioma poor prognosis-related mRNAs were submitted to the STRING version 11.0 (https://string-db.org/) database to develop the PPI network, species were restricted to Homo sapiens with medium confidence > 0.4, and isolated targets were removed. Then, the PPI network map was imported into Cytoscape 3.8.2 software for visualization, and the top 10 hub genes were analyzed by means of the cytoHubba plug-in. We further combined the glioma data in the GTEx and TCGA databases to compare expression level profiles for these 10 hub genes (glioma and healthy tissue). The Molecular Complex Detection (MCODE) app was employed for screening hub gene modules within the PPI network. Then, we used the GSVA R package to analyze the relationship between these 10 mRNAs and the degree of immune cell infiltration.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was isolated with TRIzol® (Invitrogen™, USA). The quality of total RNA was assessed using a NanoDrop® 1000 Spectrophotometer (Thermo Fisher Scientific™, USA). First-strand cDNA was prepared using the QuantiTect® Reverse Transcription Kit (QIAGEN™, USA). Actual RT-qPCR runs were conducted through qPCR SYBR Green Mix® (Bio-Rad™, USA) and the ABI 7500® platform (Applied Biosystems™, USA). PCRs were conducted using three technical replicates/sample, with resulting data assessed through the 2−ΔΔCt methodology [18]. GAPDH served as a normalizing/reference gene for circRNA, mRNA and circRNA, while U6 served as a reference for circRNA. Primers consisted of GAPDH: 5′-AGAAGGCTGGGCT CATTGG-3′ (forward) and 5′-AGGGGCCATCCACAG TCTTC-3′ (reverse); U6: 5′-CTCGCTTCGGCAGCACA-3′ (forward) and 5′-AAC GCTTACGAATTTGCG T-3′ (reverse).

Cell treatment and transfection
SiRNAs targeting circRNA-Serpine2, miR-124-3p/KIF20A mimics and inhibitors were procured through GenePharma (JiangSu, China). Such oligonucleotides/vectors underwent transient transfection using LipoFectamine 3000® (Invitrogen™, USA) following the
manufacturer’s protocols. Regarding circRNA-Serpine2 knockdown, GSC23 cellular aliquots were transfected with 20 nM siRNA against circRNA-Serpine2. MiR-124-3p/KIF20A overexpression or knockdown was achieved with 20 nM miR-124-3p/KIF20A mimic or inhibitor in A172 cells. GSC23, A172 and U251 cells underwent transduction for 24 h. Consequently, qPCR was conducted to validate altered circRNA/miRNA/mRNA expression within stabilized cells.

**Western blot**
Cellular lysis was conducted using RIPA® buffer (CWBio™, Beijing, China). Lysates were consequently placed into loading buffer and denatured (100 °C for 10 min). The resulting solutions were exposed to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), followed by transfer onto polyvinylidene difluoride (PVDF) membranes (Millipore™, Billerica, Massachusetts, USA). Following a 60-min blocking step, the membranes were placed into an incubator overnight at 4 °C in tandem with selected primary antibodies (Abcam™, Cambridge, MA, USA). Consequently, the relevant secondary antibody (CST™, Danvers, MA, USA) was introduced, and the membrane was kept at room temperature for 120 min. Proteomic loads were assessed using Immobilon Western Chemiluminescent HRP Substrate® (Millipore™, USA). The GAPDH signal was used as a loading control.

**Cell proliferation assay**
For clone formation assays, transfected cells were seeded within 6-well plates and grown in medium with 10% FBS at 37 °C/5% CO₂. Following a 10-day incubation period, cells were stained using 0.1% crystal violet (Beyotime™, Beijing, China), followed by manual colony counting.

**Cell migration assay**
A172 cells were grown within 6-well plates together with circ-siRNAs, miRNA inhibitors or mRNA mimics according to the manufacturer’s instructions. Seventy-two hours later, serum-free DMEM was introduced to the plates for 12 h. All cells were seeded in marked plates and subjected to three consecutive wash steps using sterile PBS, and monolayers were scratched (plate central region) using 200-μL pipettor tips. After incubation under normal conditions for 24 h, the cells were evaluated microscopically. All assays were performed on three separate occasions.

**Apoptosis assay**
A172 cells were harvested, washed in PBS and incubated with an Annexin V-FITC Apoptosis Detection Kit® (Beyotime Biotech™, Haimen, China) 48 h after transfection. Annexin V-FITC acted as a cell-staining agent, followed by resuspension into binding buffer (190 μL) prior to the introduction of 10 μL of PI (20 μg/mL). Consequently, the cells were incubated (15 min/dark conditions/RT) and then assessed through flow cytometry and FACS-Diva® software (Version 6.2). Cell types were separated/grouped into viable, necrotized, and apoptotic cells, and the percentages of apoptotic cells within individual groups were determined.

**Xenograft study**
Ten BALB/c nude murines (with 200 μL of cell suspension per mouse, 21 days old) were segregated in a random manner into two groups. In the control group, A172 cells were subcutaneously introduced within the right anterior flank of each mouse continuously for a five-day period. Concomitantly, circ-Serpine2 knockout exosomes were collected and injected across subcutaneous tumor circumferences at 0, 6, 12, 18, and 24 days post A172 injection. In the experimental group, mice were subcutaneously treated with A172 cells and GSC23 exosomes as described above. Day 6, 12, 18, 24 and 30 postsubcutaneous injection of A172 cells served as assessment time points, where tumor size was measured through calipers, and tumor volume (mm³) was assessed accordingly: length × width²/2.

Thirty days posttreatment, all mice were euthanized (pentobarbital sodium by intraperitoneal injection, 150–200 mg/kg). Murine tumors were removed and weighed, with sections collected, hematoxylin/eosin stained and placed for observation under microscopy measures.

**Statistical analysis**
Statistical analysis was conducted using SPSS 21.0® (Chicago, IL, USA). Major circRNA dysregulations were
assessed through R. Limma packages/FDR filtering were employed for comparative analyses. A P-value < 0.05 and absolute fold change > 2 were deemed to confer statistical significance. The chi-square test was used to assess the interactions of mRNA expression level and clinical characteristics.

Results
Discovery of specifically expressed circRNAs in GSC23
CircRNAs in GSC23 and GSC23-differentiated cell-secreted exosomes were sequenced, and scatter, box, and volcano plots, as well as hierarchical clustering, were used to visualize differential expression patterns (Fig. 1). Candidate upregulated circRNAs were analyzed using primer screening and RT-PCR. Through microarray technology and the limma package in R, we identified differentially expressed circRNAs, and the results showed that compared with differentiated GSC23 cells, GSC23 cells had 2270 abnormally expressed circRNAs (1182 significantly upregulated; 1088 significantly downregulated). These abnormally expressed circRNAs were visualized in the form of heatmaps and volcano plots (Fig. 2A, B).

Construction of the GSC23-glioma-specific circRNA-miRNA regulatory network
In the analysis, a total of 75 abnormally expressed miRNAs were identified (34 upregulated; 41 downregulated). We visualized the abnormally expressed miRNAs in glioma cells with heatmaps and volcano plots (Fig. 2C, D). Then, we preliminarily screened 450 miRNAs and selected 11 miRNAs from among them (i.e., hsa-miR-124-3p, hsa-miR-129-1-3p, hsa-miR-139-5p, hsa-miR-139-5p, hsa-miR-139-5p, hsa-miR-330-3p, hsa-miR-346, hsa-miR-485-3p, hsa-miR-485-5p, hsa-miR-543, hsa-miR-628-5p, hsa-miR-330-3p, hsa-miR-346, hsa-miR-760) (Fig. 2E). Finally, we used Cytoscape 3.8.2 to draw the regulatory networks of highly expressed circRNAs-miRNAs in GSC23 (Fig. 2F).

Construction of the GSC23-glioma-specific miRNA-mRNA regulatory network
We identified 3600 abnormally expressed mRNAs (1913 upregulated; 1687 downregulated). Abnormally expressed mRNAs in glioma cells were visualized by means of heatmaps and volcano plots (Fig. 3A, B). Then, we screened a total of 267 target mRNAs (Fig. 3C). Finally, we used Cytoscape 3.8.2 to draw the GSC23-glioma-specific miRNA-mRNA regulatory network that may be involved in glioma gene regulation (Fig. 3D).

Functional exploration of mRNAs in the GSC23-specific miRNA-mRNA regulatory network
GO analysis demonstrated 267 mRNAs to be predominantly correlated with extracellular structure organization, extracellular matrix organization, deregulation of mitotic cell cycle and other biological processes, focal adhesion, cell-substrate adherens junction, cell-substrate junction, nucleoside binding, amide binding, G protein-coupled receptor binding and other molecular functions (Fig. 4A, B). KEGG pathway-enrichment analysis results suggested that these 267 mRNAs were significantly enriched within cancer-related pathways, such as ECM-receptor interaction, apoptosis and DNA replication (Fig. 4C, D). These results suggested that circRNAs specifically expressed in GSC23 may regulate these pathways through miRNA-mRNA networks, thus affecting glioma progression.

Construction of the GSC23-glioma-unique circRNA-miRNA-mRNA regulatory network
This study discovered 144 mRNAs intimately linked to glioma patient prognosis (P < 0.001), among which 141 highly expressed mRNAs indicated a poor prognosis (hazard ratio > 1), revealing that these 141 mRNAs can be used as poor prognostic factors for glioma. Then, we constructed a PPI network and imported a PPI network diagram into Cytoscape3.8.2 software for visualization (Fig. 4E). Additionally, we identified the top 10 hub genes (AURKA, KIF20A, KIF2C, RAD51AP1, CENPN, ESPL1, HJURP, BIRC5, CDC2A2 and ZWINT) (Fig. 4F). Through the GTEx and TCGA databases, this study revealed that the expression profile of 10 hub genes was significantly upregulated in glioma tissue compared with NC tissue, providing further evidence that such a gene network can have pivotal parts in glioma progression (Fig. 5A). Therefore, we hypothesize that highly expressed circRNAs in GSC23 are transported to glioma cells and have pivotal roles in glioma tumor development by regulating these 10 hub genes through miRNAs. Finally, we constructed a circRNA-miRNA-mRNA regulatory network with plausible links to circRNAs highly expressed in GSC23 (Fig. 5B).

Finally we constructed a circRNA-miRNA-mRNA network (including 8 circRNAs, 6 miRNAs and 10 mRNAs). In general we fitted RNA expression in glioma stem cells and glioma cells (circRNA up-regulated in GSC cells, miRNA down-regulated in glioma cells, mRNA up-regulated in
Fig. 1 (See legend on previous page.)
Fig. 2  Discovery of circRNAs specifically expressed in GSCs and construction of a GSC-specifically expressed circRNA-miRNA regulatory network. 

A, B Abnormal circRNA expression in GSC23 was demonstrated in the heat map and volcano plot. C, D The dysregulated miRNA expression profile in glioma cells is demonstrated in the heat map and volcano plot. E We screened out 11 target miRNAs. F Cytoscape 3.8.2 was used to draw the GSC23-highly expressed circRNA-miRNA regulatory networks.
Fig. 3 Construction of a GSC23-specifically expressed miRNA-mRNA regulatory network. A, B The abnormal expression of mRNA in glioma cells is demonstrated in the heat map and volcano plot. C In total, 267 target mRNAs were screened out. D Cytoscape 3.8.2 was used to draw the miRNA-mRNA regulatory network associated with highly expressed circRNAs in GSC23 that may be involved in the progression of glioma.
glioma cells) and RNA target prediction together, to construct the circRNA-miRNA-mRNA network.

**Immunocorrelation analysis**

Through immunocorrelation analysis, we found that these 10 mRNAs were negatively correlated with most of the infiltrating immune cells, suggesting that the high expression of these genes in glioma may inhibit tumor immunotherapy (Fig. 5C).

CircRNA-Serpine2 upregulates KIF20A expression by sponging miR-124–3p within gliomas. Compared with their levels in A172 cells, circ-Serpine2 was significantly upregulated in GSC23 cells, while compared with their levels in SVG cells, miR-124-3p was significantly downregulated and KIF20A was significantly upregulated in A172 cells (Fig. 6A). We investigated the subcellular localization of circ-Serpine2 to determine specific roles leading to glioma development. The results showed that circ-Serpine2 was localized predominantly to the cytoplasm of A172 cells, suggesting that it could regulate glioma physiology and pathology in posttranscriptional ways (Fig. 6B). MiR-124-3p upregulation and KIF20A downregulation were accompanied by the knockdown of circ-Serpine2. Overexpression of circ-Serpine2 upregulated KIF20A expression (Fig. 6C). Moreover, in our study, we added GSC23-secreted exosomes and GSC23-secreted exosomes deficient in circ-Serpine2 to A172 and U251 cells for coculture and co-transfected them with miR-124-3p/KIF20A inhibitor/mimics. The results indicated that circ-Serpine2 knockdown drastically reduced KIF20A levels in A172 cells, while inh-miR-124-3p inhibitor and KIF20A mimics could rescue this effect; furthermore circ-Serpine2 upregulation could promote KIF20A expression in U251 cells, whereas miR-124-3p mimics and KIF20A inhibitor could reverse this effect (Fig. 6D). In summary, such datasets provide evidence that circ-Serpine2 is a target of miR-124-3p as a miRNA sponge for eventual KIF20A upregulation.

**Circ-Serpine2 promotes glioma cell progression through the miR-124-3p/KIF20A nexus**

In the functional verification section, GSC23-secreted exosomes were added to the normal control group, GSC23-secreted exosomes deficient in circ-Serpine2 were added to the si-circ group, GSC23-secreted exosomes deficient in circ-Serpine2 and miR-124-3p inhibitor were added to the si-circ + inh-miRNA group, and GSC23-secreted exosomes deficient in circ-Serpine2 and KIF20A mimics were added to the si-circ + miRNA group.

Clone forming assay dataset outcomes demonstrated that silencing circ-Serpine2 drastically reduced colony-forming capacity within A172 cells (Fig. 6E). The scratch assay suggested that circ-Serpine2 knockdown could thwart cell migration capacity (Fig. 6F). Regarding the Transwell assay, invasive cell abundance was drastically lowered in the si-circ-Serpine2 group. Moreover, in WB assay GSC23-secreted exosomes deficient in circ-Serpine2 were added in A172 group, while GSC23-secreted exosomes were added in A172 EXO group, the analysis demonstrated proteomic expression levels of N-cadherin, Vimentin, and MMP9 to be upregulated, while E-cadherin was decreased within A172 cells containing GSC23-secreted exosomes (Fig. 6G). Such outcomes indicated that circ-Serpine2 promoted glioma proliferation, together with migration/invasion in vitro.

To further validate this novel regulatory interaction between circ-Serpine2, miR-124-3p and KIF20A, this study also focused on the proliferative, migration and invasive capacities of A172 cells post-transfected with inh-miR-124-3p/KIF20A mimics. Outcomes suggested that miR-124-3p downregulation/KIF20A upregulation can recover si-circ-Serpine2-restricted proliferative, migration and invasive capacities (Fig. 6E–G). This evidence led to the conclusion that circ-Serpine2 promotes glioma cell proliferation, migration and invasion across the miR-124-3p/KIF20A nexus.

Circ-Serpine2 thwarted apoptosis within gliomas via the miR-124-3p/KIF20A nexus

The apoptotic ratio was higher in the si-circ-Serpine2 group, while cotransfection with miR-124-3p inhibitor/KIF20A mimics reversed this effect. In WB assay GSC23-secreted exosomes deficient in circ-Serpine2 were added in A172 group, while GSC23-secreted exosomes were added in A172 EXO group, the Bcl-2 proteomic level was exacerbated while cleaved-caspase3/cleaved-caspase9 levels were reduced within cells exposed to GSC23 secreted exosomes (Fig. 6H). These results proved that circ-Serpine2 may thwart apoptosis within gliomas through miR-124-3p binding and upregulation of KIF20A.
Fig. 4 (See legend on previous page.)
Circ-Serpine2 downregulation induced glioma growth regulation in vivo

The results showed that in comparison to murines treated with normal A172 cells and GSC23 exosomes, tumor weight/volume readings were drastically reduced among tumor-carrying murines subjected to A172 and circ-Serpine2-deficient exosomes (Fig. 7A, B, D), with tumor weight analyses demonstrating statistical significance (P < 0.05). The time-dependent measurements reflected a considerable reduction in tumor development (Fig. 7C). HE staining demonstrated apoptotic activity within samples to be highly exacerbated within the si-circ-Serpine2 group (Fig. 7E). Further validating the capacity of circ-Serpine2 to accelerate glioma expansion in vivo.

Discussion

High-grade gliomas are typically linked to weak prognosis and poor median survival times. An improved understanding of the mechanisms promoting glioma malignancy is needed to increase the efficacy of treatment [19–23], and accumulative evidence suggests that GSCs may participate glioma progression. Although an increasing number of biomarkers have been discovered, the relationship between GSCs and glioma progression is still unclear.

Previous studies have revealed that circRNAs, often termed miRNA sponges, possess differing miRNA response elements (MREs) that allow binding onto miRNAs, consequently downregulating cytoplasmic miRNAs and ultimately derepressing downstream targeted transcripts. In recent decades, various critical roles for circRNAs in tumor progression have been revealed. For example, Bian demonstrated that circRNA_103809 regulates colorectal cancer growth and migration [24]. Gao found that overexpression of hsa_circ_101280 upregulated the miR-124 target gene JAK2, which accelerated cellular proliferative properties [25]. CircZFR was identified to interact with C8orf4 by sponging miR-1261 in papillary thyroid carcinomas [26]. However, until now, the effects of circRNAs on the progression of glioma and their related mechanisms have rarely been reported. It has been postulated that glioma-derived exosomes may modulate target cells via the transfer of materials such as proteins, miRNAs, and noncoding RNAs [27–33]. This study focused on the possibility of GSC stemming exosomes being implicated in promoting glioma advancement through circRNA transport.
Until now, the precise functions of GSC-expressed circRNAs within glioma have remained uncertain. To establish whether GSCs expressing circRNAs could act as ceRNAs within glioma, this study initially conducted circRNA sequencing and used microarray data and the limma package in R to perform a differential analysis between GSC23 and differentiated GSC23 samples. A circRNA-miRNA-mRNA regulatory network was consequently developed, founded upon predictive models in biology, and prepared a model PPI network for DEmRNAs. In addition, circRNA-miRNA-hub and miRNA-mRNA gene subnetworks were also developed and found to regulate modules flagged within the circRNA-miRNA-mRNA network.

Through functional enrichment experiments, mRNA functional exploration, CGGA data, Kaplan–Meier survival analysis, PPI network and immune-related research, we finally identified eight circRNAs (hsa_circ_001588, hsa_circ_000898, hsa_circ_001484, hsa_circ_001101, hsa_circ_001501, hsa_circ_000735, hsa_circ_001714), six miRNAs (hsa-miR-124-3p, hsa-miR-129-1-3p, hsa-miR-346, hsa-miR-485-5p, hsa-miR-495-3p, hsa-miR-760) and ten mRNAs (AURKA, KIF20A, KIF2C, RAD51AP1, CENPN, PLES1, BIRC5, BIRC5, hsa-ZWINT) that can have pivotal parts within KIF20A progression. This investigation identified that KIF20A showed significantly high expression in glioma tissues, which suggested that this hub gene could have an essential place for exacerbating glioma expansion. Additionally, its expression was negatively correlated with infiltrating immune cells, which indicated that its high expression may inhibit tumor immunotherapy.

Previous studies have explored the regulatory effects of related circRNAs, miRNAs, and mRNAs on tumor occurrence and development. For example, Valentina reported that Serpine2 influences glioma cell migrative/invasive properties by regulating uPA and MMP-9/2 levels [34]. Vaillant analysis showed that Serpine2...
boosts the malignant progression of PNLs to medulloblastomas [35]. Wu reported that miR-124-3p could impede malignant phenotypic manifestations within gliomas through inhibition of EphA2 [36]. Lang found drastic miR-124 downregulation in GSCs compared with NSCs. Liu reported that miR-124-3p promoted apoptosis and growth inhibition in GSCs [37]. Zhou reported that KIF20A was a hub gene and mainly played a part within the cell cycle and p53 signaling activities [38]. Saito reported that KIF20A was significantly upregulated, particularly within glioma tissues, throughout the process of cellular mitotic activities. In silico analyses identified KIF20A to be upregulated within gliomas, according to tumor grade, with glioma patients having upregulated KIF20A experiencing poor prognoses. Downregulation of KIF20A decreased cellular proliferative properties within gliomas through lack of cytokinesis binucleated cell development. Moreover, KIF20A blockade led to enhanced apoptotic activity within SF126 glioma cells [39].

Through circRNA sequencing and differential analysis, we found that hsa_circ_001588 (Serpine2) was highly upregulated in GSC23 compared to glioma cells, miR-124-3p was severely downregulated in glioma cells, and KIF20A was significantly upregulated in gliomas. By constructing a GSC-specifically expressed circRNA-miRNA-mRNA regulatory network and performing mRNA functional exploration and immune-correlation analysis, we further discovered that circ-Serpine2 may competitively inhibit miR-124-3p expression and eventually influence KIF20A expression, which could promote glioma malignant progression and suppress glioma immunotherapy.

In our signaling pathway regulation experiment, we found that the silencing of circ-Serpine2 could increase miR-124-3p expression and decrease KIF20A expression in glioma cells. Subsequently, Western blotting demonstrated that circ-Serpine2 knockdown could downregulate KIF20A, with miR-124-3p cosilencing and KIF20A mRNA providing restoration of such reduced activity. In contrast, overexpression of circ-Serpine2 elevated KIF20A levels, and cotransfection with either miR-124-3p mimics or si-KIF20A reversed this effect. Taken together, these data indicated that circ-Serpine2 upregulates the KIF20A downstream signaling pathways by sponging miR-124-3p.

Functional analyses revealed that circ-Serpine2 knockdown reduced glioma proliferative, migrative and invasive properties in vitro. Such a circ-Serpine2-induced reduction could be counteracted by downregulating miR-124-3p and upregulating KIF20A expression. Reducing circ-Serpine2 expression also promoted glioma apoptosis and was rescued through a miR-124-3p inhibitor or KIF20A mimics.

The animal model analysis showed that circ-Serpine2 downregulation resulted in reduced tumor volumes and weights. Examination of HE-stained tumor sections showed increased numbers of apoptotic cells after circ-Serpine2 silencing. These findings indicated that circ-Serpine2 can promote tumor growth in vivo.

In conclusion, in this research, we identified differentially expressed circRNAs and constructed a
circRNA-miRNA-mRNA regulatory network that putatively participates in glioma cell regulation. Then, we demonstrated that GSC23 cell exosome-secured circ-Serpine2 can exacerbate KIF20A expression by sponging miR-124-3p, thus promoting glioma proliferation, migration and invasion in vitro and inhibiting glioma apoptosis in vitro. In addition, our research indicated that circ-Serpine2 inhibited glioma apoptosis and promoted tumor expansion in vivo. Such evidence indicated that circ-Serpine2 modulates glioma malignancy through the miR-124-3p/KIF20A nexus. Based on these experimental results, we could develop novel predictive/prognostic biomarkers and drug target-based therapeutic strategies in glioma clinical management.

Acknowledgements
My deepest gratitude goes first and foremost to Professor Qing Lan, my supervisor, for his constant encouragement and guidance. He has walked me through all the stages of the writing of this thesis. Without his consistent and illuminating instruction, this thesis could not have reached its present form. Second, my thanks would go to my beloved family for their loving considerations and great confidence in me throughout these years. I also owe my sincere gratitude to my friends and my fellow classmates who gave me their help and time in listening to me and helping me work out my problems during the difficult course of the thesis.

Authors’ contributions
GL proceeded with an in vitro/vivo experiment, analyzed the results, and performed gene sequencing and bioinformatic analysis. QL review and correct the manuscript. Both authors read and approved the final manuscript.

Funding
This research was supported by the General Project of Natural Science Research in Colleges and Universities of Jiangsu Province (Project No: 19KJD520002).

Availability of data and materials
Once the article is accepted by the Journal, our circRNA sequencing results will be uploaded to NCBI SRA database. The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Dr. Guowei Li and Qing Lan promised that the study was performed according to international, national and institutional rules considering animal experiments, clinical studies and biodiversity rights. The procedures for the care and use of animals were approved by the Ethics Committee of The Second Affiliated Hospital of Soochow University, and all applicable institutional and governmental regulations concerning the ethical use of animals were followed (No.JN.No20190325B00460, Date: March 05 2020). All experimental procedures were conducted in accordance with local guidelines on the ethical use of animals and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Consent for publication
Not applicable.

Competing interests
Nonfinancial competing interests.

Received: 30 August 2021   Accepted: 15 October 2021
Published online: 24 October 2021

References
1. Chang Y, Wu Q, Tian T, et al. The influence of SRPK1 on glioma apoptosis, metastasis, and angiogenesis through the PI3K/Akt signaling pathway under normoxia. Tumour Biol. 2015;36(6):6083–93.
2. Liu M, Dai B, Kang SH, et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006;66(7):5393–602.
3. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013;15:i1–56
4. Goedenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2011;205:613–21.
5. Barbagallo D, Caponnetto A, Brevi D, et al. CircSMARCAS regulates VEGFA mRNA Splicing and angiogenesis in glioblastoma multiforme through the binding of SRSF1. Cancers. 2019;11(2):194.
6. Wank M, Schilling D, Schmid TE, et al. Human glioma migration and infiltration properties as a target for personalized radiation medicine. Cancers. 2018;10(1):456.
7. Chen TC, da Fonseca CO, Schönthal AH. Intranasal perillyl alcohol for glioma therapy: molecular mechanisms and clinical development. Int J Mol Sci. 2018;19(12):3905.
8. van Ierschot F, Bastaanse R, Michel G. Evaluating splicing in glioma patients undergoing awake surgery: a systematic review. Neuropsychol Rev. 2018;28(4):470–95.
9. Ostrom QT, Baecht L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16(7):896–913.
10. Chan XH, Nama S, Gopal F, et al. Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas. Cell Rep. 2012;2(3):591–602.
11. Huang Z, Cheng L, Guryanova OA, et al. Cancer stem cells in glioblastoma–molecular signaling and therapeutic targeting. Protein Cell. 2010;1(7):638–55.
12. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843–8.
13. Wang J, Chen S, Ma X, et al. Effects of endothelial progenitor cell-derived microvesicles on hypoxia/reoxygenation-induced endothelial dysfunction and apoptosis. Oxid Med Cell Longev. 2013;2013:572729.
14. Wang X, Gu H, Huang W, et al. Hsp20-mediated activation of oxidative biogenesis in cardiomyocytes improves cardiac function and angiogenesis in diabetic mice. Diabetes. 2016;65:3111–28.
15. Ribeiro MF, Zhu H, Millard RW, et al. Exosomes function in pro- and anti-angiogenesis. Curr Angiogenes. 2013;3:54–9.
16. Otsuki T, Ishikawa M, Hori Y, et al. Volatile anesthetic sevoflurane ameliorates endotoxin-induced acute lung injury via microRNA modulation in rats. BioMed Rep. 2015;3(3):408–12.
17. Ma ZL, Hou PP, Li YL, et al. MicroRNA-34a inhibits the proliferation and promotes the apoptosis of nonsmall cell lung cancer H1299 cell line by targeting TGFBetaR2. Tumour Biol. 2015;36(4):2481–90.
18. Brower JV, Clark PA, Lyon W, et al. MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. Neurochem Int. 2014;77:68–77.
19. Li Q, Wang AQ, Xu QG, et al. In-vitro inhibitory effect of EGFL7-RNAi on endothelial angiogenesis in glioma. Int J Clin Exp Pathol. 2015;8(10):12234–42.
20. Dwekman M, Mehan W, Niemierko A, et al. The treatment-related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2019;142(1):69–77.
21. Noorlag L, De Vos FY, Kok A, et al. Treatment of malignant gliomas with ketogenic or caloric restricted diets: a systematic review of preclinical and early clinical studies. Clin Nutr. 2019;38(5):1986–94.
22. Liu H, Li C, Yang L, et al. Long noncoding RNA CASC9/miR-519d/STAT3 positive feedback loop facilitate the glioma tumorigenesis. J Cell Mol Med. 2018;22(12):6338–44.
23. Sun X, Wang J, Huang M, et al. STAT3 promotes tumour progression in glioma by inducing FOXO1 transcription. J Cell Mol Med. 2018;22(11):5629–38.
24. Bhatnagar A, Li X, Ma L, et al. Hsa_circRNA-103809 regulated the cell proliferation and migration in colorectal cancer via miR-532-3p/FOXO4 axis. Biochem Biophys Res Commun. 2018;505(2):346–52.
25. Cao S, Wang G, Wang J, et al. Hsa_circ_101280 promotes hepatocellular carcinoma by regulating miR-375/JAK2. Immunol Cell Biol. 2019;98(2):218–28.
26. Wei H, Pan L, Tao D, et al. Circular RNA circZFR contributes to papillary thyroid cancer cell proliferation and invasion by sponging miR-1261 and facilitating C8orf4 expression. Biochem Biophys Res Commun. 2018;503(1):56–61.
27. Domenis R, Cesselli D, Toffoletto B, et al. Systemic T Cells immunosuppression of glioma stem cell-derived exosomes is mediated by monocytic myeloid-derived suppressor cells. PLoS ONE. 2017;12(1):e0169932.
28. Gong M, Yu B, Wang J, et al. Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis. OncoTarget. 2017;8(28):45200–12.
29. Li MY, Liu DW, Mao YG. Advances in the research of effects of exosomes derived from stem cells on wound repair. Zhonghua Shao Shang Za Zhi. 2017;33(3):180–4.
30. Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009;100(10):1603–7.
31. Bobrie A, Colombo M, Raposo G, et al. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic. 2011;12(12):1659–68.
32. Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Madrid F, et al. Analysis of microRNA and protein transfer by exosomes during an immune synapse. Methods Mol Biol. 2013;1024:41–51.
33. Figueroa J, Phillips LM, Shahar T, et al. Exosomes from glioma-associated mesenchymal stem cells increase the Tumorigenicity of glioma stem-like cells via transfer of miR-1587. Cancer Res. 2017;77(21):5808–19.
34. Pagliara V, Adornetto A, Mammi M, et al. Protease nexin-1 affects the migration and invasion of C6 glioma cells through the regulation of urokinase plasminogen activator and matrix metalloproteinase-9/2. Biochim Biophys Acta. 2014;1843(11):2631–44.
35. Vaillant C, Valdivieso P, Nuciforo S, et al. Serpine2/PN-1 is required for proliferative expansion of pre-neoplastic lesions and malignant progression to medulloblastoma. PLoS ONE. 2015;10(4):e0124870.
36. Wu Q, Xu L, Wang C, et al. MicroRNA-124-3p represses cell growth and cell motility by targeting EphA2 in glioma. Biochem Biophys Res Commun. 2018;503(4):2436–42.
37. Liu S, Yin F, Zhang J, et al. Regulatory roles of miRNA in the human neural stem cell transformation to glioma stem cells. J Cell Biochem. 2014;115(8):1368–80.
38. Zhou Y, Yang L, Zhang X, et al. Identification of potential biomarkers in glioblastoma through bioinformatic analysis and evaluating their prognostic value. Biomed Res Int. 2019;2019:6581576.
39. Saito K, Ohta S, Kawakami Y, et al. Functional analysis of KIF20A, a potential immunotherapeutic target for glioma. J Neurooncol. 2017;132(1):63–74.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.